摘要
溴隐亭广泛应用于垂体泌乳素瘤,是其首选口服药物,但妊娠期和哺乳期应用溴隐亭的安全性尚无明确定论。本文归纳既往临床研究数据来总结妊娠期和哺乳期患者应用溴隐亭的安全性。大量资料表明妊娠早期泌乳素瘤患者应用溴隐亭可以降低流产率,不会增加胎儿和新生儿的潜在风险,仅有少数资料结果与此相反;曾有产妇哺乳期应用溴隐亭产生严重副作用的报道,目前尚无证据表明哺乳会使泌乳素瘤患者肿瘤增大,在考虑肿瘤大小和症状等个体情况下哺乳并非禁忌,但不推荐哺乳期进行溴隐亭治疗。
Bromocriptine is widely used in pituitary prolactinoma and is the oral drug of choice. However, the safety of bromocriptine during pregnancy and lactation has not been clearly determined. In this paper, data from previous clinical studies were summarized to summarize the safety of bromocriptine in pregnant and lactating patients. A large number of data show that bromocriptine can reduce the rate of miscarriage in patients with prolactinoma in early pregnancy without increasing the potential risk to the fetus and newborn, and only a few data show the opposite result;there have been reports of serious side effects of bromocriptine during lactation. Currently, there is no evidence that breastfeeding can increase the tumor size of prolactinoma patients. Breastfeeding is not contraindicated considering individual circumstances such as tumor size and symptoms, but bromocriptine therapy during lactation is not recommended.
出处
《世界肿瘤研究》
2023年第4期144-149,共6页
World Journal of Cancer Research
